New Data on Ultra Low-Dose Estradiol Therapy in Osteoporosis Prevention New Data on Ultra Low-Dose Estradiol Therapy in Osteoporosis Prevention Marie Foegh,

Slides:

Advertisements

Similar presentations

{ Dose Response to Vitamin D Supplementation in Postmenopausal Women Annals of Internal Med. 2012; 156: Jayme Bristow.

Advertisements

Osteoporosis Daniel K. Park, MD. Osteoporosis Weakening of the bones.

© 2013 North American Menopause Society. Menopause. 2013;20(9): Key points from the 2013 Position Statement of The North American Menopause Society.

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.

Adam M. Brufsky, MD, PhD Co-Director, Comprehensive Breast Cancer Center Magee-Women’s Hospital University of Pittsburgh Medical Center Pittsburgh, Pennsylvania.

Pilot and Pharmacokinetic Studies of Solubilized Estradiol Administered Vaginally in a Softgel Capsule James H. Pickar, M.D., F.A.C.O.G.

Long-term Safety and Effectiveness of Natalizumab STRATA MS Study.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

1 Efficacy of Testosterone Transdermal System (TTS) for Treatment of HSDD in Surgically Menopausal Women on Concomitant Estrogen Daniel Davis, MD, MPH.

Downloaded from 1 Alendronate vs. Risedronate Comparison Trial.

Slide 1 Update on Alendronate and Raloxifene in Osteoporosis EFficacy of FOSALAN ™ vs. Evista ® Comparison Trial (EFFECT) FOSALAN (alendronate) is a trademark.

HRT In a nutshell for all the blokes out there. diagnosis  Clinical hx  FSH limited value as levels fluctuate  May be of value in symtomatic women.

Post Menopausal Bleeding

Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.

For the Treatment of Uterine Fibroids and Endometriosis

 The term post menopause is applied to women who have not experienced a menstrual bleed for a minimum of 12 months, assuming that they do still have.

Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham.

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,

Hormonal Replacement Therapy for postmenopausal females: To give or not to give? Amna B. Buttar, MD, MS Assistant Professor of Clinical Medicine Indiana.

Hormone Replacement Therapy 5/11/07 5/11/07Tanu. History of HRT Approximately 100years of research and 80 years of clinical practice Ovarian extracts.

1 Study of Tamoxifen and Raloxifene STAR Larry Wickerham, MD NSABP STAR Project Officer.

Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.

A High Prevalence of Vitamin D Inadequacy in a Minimal Trauma Fracture Population A High Prevalence of Vitamin D Inadequacy in a Minimal Trauma Fracture.

TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.

Medication Options H ealthPLACE/HOPE Program COPYRIGHT © 2002 Highmark Inc. All Rights Reserved. These materials may not be copied or otherwise reproduced.

Advances in osteoporosis treatment John C Stevenson National Heart & Lung Institute Imperial College London Royal Brompton Hospital London, UK.

Download from Slide 1 Update on Alendronate and Raloxifene in Osteoporosis EFficacy of Fosamax ™ vs. Evista ® Comparison.

Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.

Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

MacLennan Selected Risks and Benefits after 5 Years of combined estrogen and progestogen HRT for all women aged (WHI Study, 2002) OESTROGEN WITH.

The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.

By: Erin Hutzell. Background: Breast Cancer Second leading cause of death due to cancer among women in in 3 women diagnosed with cancer is diagnosed.

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Food and Drug Administration Regulatory Implications of The WHI Study Eric Colman, MD Center for Drug Evaluation and Research Division of Metabolic and.

Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.

A Diabetes Outcome Progression Trial

Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.

Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.

FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.

Alimohammad Fatemi Assistant Professor of Rheumatology 1.

Menopausal Hormone Replacement Professor Gordana Prelevic, MD, DSc, FRCP Consultant Endocrinologist Royal Free Hampstead NHS Trust Whittington Health.

Ten Years’ Experience with Alendronate for the Treatment of Osteoporosis in Postmenopausal Women Adapted from Bone HG, Hosking D, Devogelaer J-P, Tucci.

Does a high soy intake prevent the development of osteoporosis? Elizabeth Yahn.

Prevention and Treatment of Osteoporosis

1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.

11 Androgenic AEs by Maximum Free T P hase II and Phase III % of patients Placebo N= 703 TTS Upper Decile N=58 Acne710.3 Alopecia Facial Hair55.2.

Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.

WHI Trial of Estrogen plus Progestin: Reviewer’s Comments Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville, Maryland - 7 October.

Moji Saberin-Williams, M.D. Paoli Hospital Obstetrician/Gynecologist

HORMONE REPLACEMENT THERAPY (HRT) Evidence-based Guidelines Dr Mahdy El- Mazzahy Damietta general Hospital 7 th International Annual Congress “Alexandria”

Are your bones healthy? Normal boneOsteoporosis Definition A systemic skeletal disease characterized by low bone mass and micro architectural deterioration.

Introduction Data Statistical Methods Table 1: Prevalence of Prior Hip Fracture and Incidence of New Hip Fractures and Fractures of Any Type.

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

Treatment of Vitamin D Insufficiency in Postmenopausal Women: A randomized clinical trial Journal Club 1/8/2016 Sharda Mukunda.

European Society of Cardiology 2017 Clinical Trial Update I

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Mostafa AL Turk Tatiana Hawat

Menopause Paul Beck, MD, FACOG, FACS.

A Low Carbohydrate Nutritional Program Improves Weight, Insulin, and Estrogenic Parameters in Obese Patients with Estrogen Receptor Positive Endometrial.

Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.

Section 7: Aggressive vs moderate approach to lipid lowering

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Deciding on Pharmacological Treatment Post Fracture

Hormone Replacement Therapy (HRT)

Deciding on Pharmacological Treatment Post Fracture

New Models of Care in Idiopathic Pulmonary Fibrosis

Presentation transcript:

New Data on Ultra Low-Dose Estradiol Therapy in Osteoporosis Prevention New Data on Ultra Low-Dose Estradiol Therapy in Osteoporosis Prevention Marie Foegh, MD, DSc VP, Medical Affairs Berlex Laboratories

Outline BackgroundBackground StudyStudy –Design –Efficacy –Safety ConclusionConclusion

Loss of Estrogen has Profound Effects on Bone Increased resorptionIncreased resorption Rapid bone lossRapid bone loss Apoptosis of osteocytesApoptosis of osteocytes Increased risk of hip & spine fractureIncreased risk of hip & spine fracture

Lowest effective dose “ for the individual patient ” Risk / BenefitRisk / Benefit Quality of LifeQuality of Life

Ultra Low Dose Transdermal Estrogen Replacement Assessment (ULTRA) UCSF Coordinating CenterUCSF Coordinating Center –Deborah Grady, Steven Cummings, Eric Vittinghoff, Judy Macer, Judy Quan, Lorie Denton InvestigatorsInvestigators –B. Ettinger (Kaiser Permanente), K. Ensrud (University of Minnesota), B. Wallace (University of Iowa), K. Johnson (University of Tennessee), P. Marx (Chicago Center for Clinical Research), S. Barbier (Seattle Women’s Clinical Research Center), J. Pinkerton (University of Virginia), M. Farmer (Meridien Research) and D. Rowe (Palm Beach Research Center)

Design Randomized, placebo-controlled, blinded trialRandomized, placebo-controlled, blinded trial 417 women (E2 n=208, placebo n=209)417 women (E2 n=208, placebo n=209) –60 to 80 years old with an intact uterus –More than 5 years post-menopausal –BMD z-score  Weekly transdermal E2 (0.014 mg/d) vs. placeboWeekly transdermal E2 (0.014 mg/d) vs. placebo –Goal to increase serum E2 to 10–15 pg/mL Daily calcium (800mg/d) and vitamin D (400 IU/d)Daily calcium (800mg/d) and vitamin D (400 IU/d) Duration of Study: 2 yearsDuration of Study: 2 years –Follow-up visits every 4 months

Effects of mg E2 on BMD 2.5%

Effects of mg E2 on BMD 1.5%

Patients with Clinical Fractures 62Other 32Wrist 00Hip 10SpinePlacebo(n=209) mg Estradiol (n=208) Fracture Location

Pooling Both “Ultra Low” Trials Clinical Fractures 166Combined** 62 Prestwood et al* 104ULTRAPlacebo Ultra Low E2 * JAMA August 27, 2003 ** S. Cummings, RR = 0.4; p = 0.04

Adverse Events: Serious

Ultra Trial Conclusion Two years of unopposed ultra low dose transdermal estradiolTwo years of unopposed ultra low dose transdermal estradiol –Prevents bone loss in older postmenopausal women –Safe for the endometrium –Decrease in markers of bone turnover –No increase in breast tenderness, headache and other common estrogen-related adverse events –No effect on C-RP, SHBG, Lipids

Paradigm Shift: Changing the Risk/Benefit Profile Ultra low dose estradiol: Fracture reduction in osteopenic patientsFracture reduction in osteopenic patients Ultra low dose unopposed safe for the endometrium for up to two yearsUltra low dose unopposed safe for the endometrium for up to two years Adverse event profile similar to placeboAdverse event profile similar to placebo –No negative GI or vasomotor effects

Markers of Bone Turnover * Change in median

Cumulative Percent with Amenorrhea

Endometrial Evaluation after 24 Months 417 Randomized Tissue diagnosis269 normal267 atypical hyperplasia 1 uterine adenosarcoma 1 Dropped out 41 placebo24 estradiol17 No tissue diagnosis107 sample lost 1 refused or unable 68 insufficient 38 Refused TVUS 6 TVUS 101 Endometrium> 5mm11 normal tissue 6 nml hysterosalpingogram 1 No further work-up 4 Endometrium< 5mm90

Baseline Characteristics EstradiolPlaceboP (n=208)(n=209) Age, years White, % College Educ, % Current smoker, % Dietary calcium, mg/day Any alcohol BMI Age at menopause, yrs

Adverse Events No significant difference of headache, nausea or genital discomfort reported (  2%)No significant difference of headache, nausea or genital discomfort reported (  2%)

Adverse Events over Two Years: N (%) 00 Death Death ( 9.6) 22 (10.6) Hospitalization Hospitalization ( 2.4) 3 ( 1.4) Cancer Cancer (11.5) Serious Adverse Events P-valuePlacebo(n=209)Estradiol (n = 208)

(10.0) 6 ( 2.9) Rash Rash ( 4.3) 1 ( 0.5) Herpes Zoster Herpes Zoster ( 3.3) 1 ( 0.5) Hernia Hernia ( 1.4) 22 (10.6) Vaginal discharge Vaginal discharge ( 0.9) 7 ( 3.4) Endometrial polyp Endometrial polyp ( 1.0) 12 ( 5.8) Cervical polyp Cervical polyp P-valuePlacebo(n=209)Estradiol (n = 208) * incidence > 2% and statistical difference between estradiol and placebo Adverse Events over Two Years: N (%)

Individualizing Therapy